Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Anti-platelet therapy is a key point of acute myocardial infarction (AMI) treatment.
Nowadays, dual anti-platelet therapy based on aspirin and ADP-P2Y12 receptor inhibitor is the
preferred treatment before primary percutaneous coronary intervention (PPCI). Restricted by
pharmacokinetic and pharmacodynamic characteristics, ADP-P2Y12 receptor inhibitors cannot
take effect immediately after oral administration. However, platelet glycoprotein Ⅱb / Ⅲa
inhibitors take effect faster. Previous clinical trials indicated that combination of full
dose of glycoprotein Ⅱb / Ⅲa inhibitor and dual anti-platelet therapy reduced AMI related
ischemia events but increased bleeding events significantly. The high dose of glycoprotein Ⅱb
/ Ⅲa inhibitor may be the key factor contributing to the increased bleeding events.
Therefore, this study aims to evaluate the effectiveness and security of triple anti-platelet
therapy based on a small dose of glycoprotein Ⅱb / Ⅲa inhibitor, aspirin and ADP-P2Y12
receptor inhibitor in AMI patients receiving PPCI.